Xermelo
Total Payments
$4.5M
Transactions
10,267
Doctors
4,426
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $58,061 | 718 | 502 |
| 2023 | $140,477 | 985 | 755 |
| 2022 | $1.2M | 1,789 | 1,086 |
| 2021 | $1.4M | 1,291 | 816 |
| 2020 | $533,441 | 650 | 434 |
| 2019 | $543,559 | 1,482 | 878 |
| 2018 | $255,577 | 1,310 | 831 |
| 2017 | $378,577 | 2,042 | 1,162 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.1M | 397 | 68.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $447,580 | 227 | 10.0% |
| Consulting Fee | $436,837 | 165 | 9.7% |
| Food and Beverage | $208,991 | 8,883 | 4.7% |
| Travel and Lodging | $137,170 | 480 | 3.1% |
| Space rental or facility fees (teaching hospital only) | $94,145 | 34 | 2.1% |
| Grant | $65,000 | 4 | 1.4% |
| Compensation for serving as faculty or as a speaker for a medical education program | $34,915 | 25 | 0.8% |
| Education | $602.88 | 52 | 0.0% |
Payments by Type
Research
$3.1M
397 transactions
General
$1.4M
9,870 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 2, Multicenter, open-label, safety and efficacy study of Xermelo (telotristat ethyl) plus first-line chemotherapy in patients with locally advanced, unresectable, recurrent or metastatic biliary tract cancer | TerSera Therapeutics LLC | $1.2M | 0 |
| TELEHEART: Telotristat Ethyl in a Heart Biomarker Study | TerSera Therapeutics LLC | $519,473 | 0 |
| LX1606.1-207-BTC | Lexicon Pharmaceuticals, Inc. | $449,529 | 0 |
| Prospective assessment of patients with neuroendocrine tumors and current or prior history of carcinoid syndrome or diarrhea undergoing peptide receptor radionuclide therapy with or without telotristat ethyl (NET-PACS Trial) | TerSera Therapeutics LLC | $441,996 | 0 |
| TPH1 | Lexicon Pharmaceuticals, Inc. | $121,593 | 0 |
| IIS Telotristat Ethyl | Lexicon Pharmaceuticals, Inc. | $53,504 | 0 |
| IIS | Lexicon Pharmaceuticals, Inc. | $52,909 | 0 |
| Role of Serotonin in Colon and Liver Cancer Growth | TerSera Therapeutics LLC | $50,250 | 0 |
| Serotonin as a biomarker to chemotherapy response in cholangiocarcinoma | TerSera Therapeutics LLC | $42,128 | 0 |
| Serotonin in Coln and Lvr Can | Lexicon Pharmaceuticals, Inc. | $35,273 | 0 |
| Pre-clinical investigation of tryptophan hydroxylase inhibitor telotristat ethyl for the treatment of cholangiocarcinoma | TerSera Therapeutics LLC | $30,398 | 0 |
| A Phase II, open-label, single-arm study of INCMGA00012 and telotristat ethyl in patients with advanced neuroendocrine tumors and carcinoid syndrome | TerSera Therapeutics LLC | $12,500 | 0 |
| Monitoring Telotristat Ethyl Inhibition of Tryptophan hydroxylase (TPH) in Neuroendocrine Tumors Using a-[11C]methyl-L-tryptophan (AMT)-PET | TerSera Therapeutics LLC | $9,925 | 0 |
| Short-Term Outcomes of a High-Volume, Low-Concentration Bolus Starting Dose Technique With Ziconotide | TerSera Therapeutics LLC | $3,825 | 1 |
| LX1606.207 BTC | Lexicon Pharmaceuticals, Inc. | $3,650 | 0 |
| Randomized, parallel arm, Phase II Study of Telotristat (Xermelo) in combination with Lutetium Lu 177 Dotatate (Lutathera) in Well Differentiated Neuroendocrine Tumors (NETs) | TerSera Therapeutics LLC | $3,558 | 0 |
| Weight Loss in Patients with Advanced Stage Pancreatic Cancer: Role of Serotonin and Effects of Telotristat Ethyl | TerSera Therapeutics LLC | $2,145 | 0 |
| LX1606.303 | Lexicon Pharmaceuticals, Inc. | $900.00 | 0 |
| The Effect of Telotristat Ethyl on RABL6A and the NAD Pathway in Neuroendocrine Tumors | TerSera Therapeutics LLC | $24.44 | 0 |
Top Doctors Receiving Payments for Xermelo — Page 7
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Hematology & Oncology | Temecula, CA | $169.95 | 7 |
| , M.D | Medical Oncology | Athens, GA | $168.48 | 8 |
| , M.D | Hematology & Oncology | San Antonio, TX | $168.23 | 10 |
| , M.D | Medical Oncology | Anderson, SC | $167.44 | 13 |
| , MD | Hematology & Oncology | Fort Wayne, IN | $167.00 | 4 |
| , MD | Medical Oncology | Spartanburg, SC | $166.62 | 9 |
| , M.D | Hematology & Oncology | Omaha, NE | $165.80 | 8 |
| , MD | Hematology & Oncology | Brockton, MA | $165.54 | 10 |
| Andrei Balandin | Hematology & Oncology | Glendale, AZ | $165.39 | 4 |
| , APRN | Acute Care | Scottsbluff, NE | $165.00 | 10 |
| , MD | Surgery | Duarte, CA | $164.21 | 2 |
| , MD | Anatomic Pathology & Clinical Pathology | Fayetteville, NC | $163.17 | 2 |
| , M.D | Hematology | Inverness, FL | $162.39 | 4 |
| , M.D | Hematology & Oncology | Sylacauga, AL | $162.36 | 11 |
| , MD | Hematology & Oncology | Wichita, KS | $160.82 | 8 |
| , MD | Hematology & Oncology | Gulfport, MS | $159.96 | 8 |
| , MD | Hematology & Oncology | Lancaster, PA | $159.78 | 8 |
| , MD | Hematology & Oncology | Huntington, WV | $157.36 | 11 |
| , MD | Hematology & Oncology | Wichita, KS | $156.46 | 8 |
| , M.D | Hematology & Oncology | Van Nuys, CA | $155.76 | 7 |
| , FNP | Family | Morristown, TN | $155.44 | 9 |
| , M.D | Internal Medicine | San Antonio, TX | $154.35 | 2 |
| , MD | Hematology & Oncology | Richmond, VA | $154.18 | 12 |
| , M.D | Specialist | Pasadena, CA | $154.06 | 6 |
| , M. D | Hematology & Oncology | Evanston, IL | $153.41 | 2 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $4.5M
- Total Doctors 4,426
- Transactions 10,267
About Xermelo
Xermelo is a drug associated with $4.5M in payments to 4,426 healthcare providers, recorded across 10,267 transactions in the CMS Open Payments database. The primary manufacturer is TerSera Therapeutics LLC.
Payment data is available from 2017 to 2024. In 2024, $58,061 was paid across 718 transactions to 502 doctors.
The most common payment nature for Xermelo is "Unspecified" ($3.1M, 68.3% of total).
Xermelo is associated with 19 research studies, including "A Phase 2, Multicenter, open-label, safety and efficacy study of Xermelo (telotristat ethyl) plus first-line chemotherapy in patients with locally advanced, unresectable, recurrent or metastatic biliary tract cancer" ($1.2M).